Drug profile · INN
ponatinib hydrochloride
PONATINIB HYDROCHLORIDE
ponatinib hydrochloride (PONATINIB HYDROCHLORIDE) is a bcr/abl fusion protein inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Drug details — ponatinib hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 15
- Data quality
- 0.89
Quick answer
ponatinib hydrochloride (PONATINIB HYDROCHLORIDE) is a bcr/abl fusion protein inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bcr/Abl fusion protein inhibitor
Primary target: Bcr/Abl fusion protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ponatinib hydrochloride?
ponatinib hydrochloride (PONATINIB HYDROCHLORIDE) is a bcr/abl fusion protein inhibitor. Associated with Takeda. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ponatinib hydrochloride?
PONATINIB HYDROCHLORIDE is a marketed brand name for ponatinib hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ponatinib hydrochloride?
ponatinib hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.